Scholarlink

<p>Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), play vital, context-specific roles in cancer, functioning as either tumor suppressors or oncogenic factors. Preliminary evidence suggests that a primary mechanism of ncRNA influence is through the interferon (IFN) signaling pathway, with a focus on how they may regulate IFN-induced immune surveillance and immunotherapy outcomes. Types I, II, and III IFNs regulate antitumor immunity, antigen presentation, and immune checkpoint activity, but can also support tumor growth in certain scenarios. Evidence indicates ncRNAs modulate IFN signaling by targeting IFN receptors, JAK–STAT components, interferon-stimulated genes (ISGs), and IRFs. Some ncRNAs suggest potential to enhance antitumor immune responses and improve responses to IFN-based therapies, while others may dampen immune activity, contribute to therapy resistance, or promote metastasis. This review centers on how ncRNAs act as tumor suppressors or promoters through modulating IFN signaling to influence immunotherapy efficacy, demonstrating their versatile roles in shaping immune surveillance across various cancers. Although encouraging, experimental findings face challenges like functional complexity, delivery barriers, and off-target effects that must be addressed before clinical application. By integrating mechanistic and translational perspectives, this review highlights potential new opportunities to target ncRNA–IFN interactions for personalized medicine and advanced immunotherapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-Coding RNAs as key regulators of interferon signaling in cancer immunotherapy: mechanistic insights and clinical prospects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Usamah Sayed,
  • Waleed K. Abdulsahib,
  • S. Renuka Jyothi,
  • Priya Priyadarshini Nayak,
  • Ashish Singh Chauhan,
  • Siya Singla,
  • Djamila Polatova,
  • Fadhil Faez Sead,
  • Reza Akhavan-Sigari

摘要

Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), play vital, context-specific roles in cancer, functioning as either tumor suppressors or oncogenic factors. Preliminary evidence suggests that a primary mechanism of ncRNA influence is through the interferon (IFN) signaling pathway, with a focus on how they may regulate IFN-induced immune surveillance and immunotherapy outcomes. Types I, II, and III IFNs regulate antitumor immunity, antigen presentation, and immune checkpoint activity, but can also support tumor growth in certain scenarios. Evidence indicates ncRNAs modulate IFN signaling by targeting IFN receptors, JAK–STAT components, interferon-stimulated genes (ISGs), and IRFs. Some ncRNAs suggest potential to enhance antitumor immune responses and improve responses to IFN-based therapies, while others may dampen immune activity, contribute to therapy resistance, or promote metastasis. This review centers on how ncRNAs act as tumor suppressors or promoters through modulating IFN signaling to influence immunotherapy efficacy, demonstrating their versatile roles in shaping immune surveillance across various cancers. Although encouraging, experimental findings face challenges like functional complexity, delivery barriers, and off-target effects that must be addressed before clinical application. By integrating mechanistic and translational perspectives, this review highlights potential new opportunities to target ncRNA–IFN interactions for personalized medicine and advanced immunotherapies.